The Down Under medical landscape is excited with the emergence of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing impressive results in early trials for treating obesity. This therapy https://auresortwear.com/2026/06/10/retatrutide-australia-my-deep-dive-into-weight-loss-treatments/